Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludeoxyglucose (18F) (University of Pennsylvania)
- Development stage
- Approved
- Lead developer
- University of Pennsylvania
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- intravenous
01
Overview
Fludeoxyglucose (18F) is a positron-emitting radiopharmaceutical and glucose analog widely used in positron emission tomography (PET) imaging. Structurally, it is a derivative of D-glucose where the hydroxyl group at the C-2 position is replaced by the radioactive isotope fluorine-18. Following intravenous administration, fludeoxyglucose (18F) is transported into cells via facilitative glucose transporters (GLUTs) and phosphorylated by hexokinase to fludeoxyglucose-6-phosphate. Because it lacks the 2-hydroxyl group required for further glycolysis, it cannot be metabolized further and becomes trapped intracellularly. This metabolic trapping allows for the visualization and quantification of regional glucose consumption, making it a cornerstone diagnostic tool in oncology (to detect and stage malignant tumors), cardiology (to assess myocardial viability), and neurology (to identify epileptogenic foci and evaluate neurodegenerative diseases).
- Brand names
- AtlantiscanCyclodxFluGlucoScanFluorOHmetGlucovisionGludefMetatrace FDG
- Other names
- 18F-FDG2-deoxy-2-[18F]fluoro-D-glucoseFDGfludeoxyglucose F 18fluorine-18 FDGfluorine18 FDGfluorine 18 FDGfluorodeoxyglucose (18F)fluorodeoxyglucose F 18
02
Targets
HK1 (Hexokinase type I (mitochondrial))HK2 (Hexokinase Type II)GLUT1 (Glucose transporter 1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on fludeoxyglucose (18F) (University of Pennsylvania).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludeoxyglucose (18F) (University of Pennsylvania).